World's First Clinical Validation of Universal iPSC-Derived Platelet Product RBT101 by Heluo Xintu

Apr 23, 2025 08:21 CST Updated 08:21

Renerval Therapeutics

Cell Therapy Technology Developer

The latest data from the IIT human clinical study of Renerval Therapeutics' self-developed universal artificial regenerated platelet product RBT101 shows,RBT101 Demonstrates Good Safety and Quantifiable Efficacy Signals in Humans.

Tackling the "Blood Shortage" Challenge:

Artificial Platelets Show Clinical Value

This IIT study completed the world's first infusion in March 2025. As of now, the clinical data shows:

In terms of safety:RBT101 demonstrated good safety in humans, with no DLT events or serious adverse events occurring.

Efficacy Trend:After the infusion of RBT101 artificial platelets, the platelet count in the body increased, and the efficacy curve showed a plateau without significant decline. The dose of RBT101 artificial platelets will be further increased and the clinical sample size expanded to further verify its effectiveness.

Science Illuminates Life, Innovation Reshapes the Future

The successful clinical infusion of RBT101 product has achieved a breakthrough from "0" to "1" in China's artificial blood field.Marking its significant potential to become the first human-derived platelet substitute product in China., which is expected to bring a revolutionary treatment method for patients with thrombocytopenia.

Renerval Therapeutics will continue to deepen its expertise in the field of cell therapy, using a comprehensive layout of the "artificial blood system" to advance transfusion medicine into a new era.Accessible, Controllable, Affordable"A New Era.

Tweet link:iPSC-Derived Platelet Technology Makes Large-Scale In Vitro Production of Platelets a Reality

About Renerval Therapeutics

Renerval Therapeutics was founded in 2021. The entrepreneurial team is led by returning scholars from the Massachusetts Institute of Technology and the University of Cambridge in the UK. It is a high-tech innovative enterprise aimed at iPSC directed differentiation, gene editing, large-scale cell product preparation, and cell therapy technology development.

Renerval Therapeutics addresses the core issues and clinical needs in the field of regenerative medicine through years of innovative cell-directed differentiation technology in the iPSC domain. The company is committed to building an artificial blood preparation platform while simultaneously developing a world-leading regenerative medicine cell product development system. The R&D team consists of young scholars from renowned universities and research institutions both in China and abroad, as well as outstanding talents with years of industry experience. The team has extensive research and industry experience in stem cells and translational medicine.

E.N.D

Previous article recommendations:(Click the article title below to open the original text)

Comprehensive Analysis of Bioprocessing and Regulatory Landscape in Stem Cell Therapy

China’s first stem cell clinical research project targeting major pediatric diseases has achieved remarkable results, enabling children with cerebral palsy to progress from being unable to stand to walking independently.

A Cell Therapy Company Opens and Begins Production in China

World's First Breakthrough Clinical Research Achievement in Treating ALS with Intrathecal Injection of Treg Cells Released

China's First Allogeneic Universal Regenerative Islet Transplantation Therapy for Type 1 Diabetes Receives IND Approval

A Cell Therapy Company in China Secures New Round of Financing

Stock Price Surges Nearly 40%! AAV Gene Therapy AMT-130 Receives Breakthrough Therapy Designation

China's First Hospital-Grade iPSC Technology Platform Launched

Hua Yi Le Jian, a gene therapy company founded by Rao Yi, announces new Chief Medical Officer

Up 135% Year-on-Year! Legend Biotech’s CAR-T Cell Therapy Product Rakes in $369 Million in Q1

Output Soars 345%! New Low-Cost Cell Culture Technology to Reshape MSC High-Efficiency Production Paradigm

A Cell Therapy Company in China Completes Tens of Millions in Angel Round Financing

Latest Clinical Progress of the World's First Glaucoma Gene Therapy – Beijing Tongren Hospital Completes Dosing in 2 Patients

Nature | New Breakthrough in Gene Editing! Achieving Highly Efficient Integration of Large Gene Fragments, May Lead to a New Generation of Gene Therapy Drugs

China's First AAV Gene Therapy Drug Approved for Marketing!

The Number of Gene Therapy Drugs Listed in China Rises to 9

CDE Releases "Common Issues and Responses on the Chemistry, Manufacturing, and Controls of Recombinant Adeno-Associated Virus Vector In Vivo Gene Therapy Products for Marketing Authorization Application (Draft for Comments)"

Construction of a GMP Facility for Cell Drug Production in China Officially Begins

Maximum Single Award of 30 Million Yuan, Focusing on Cell Drugs, Nucleic Acid Drugs, Protein Drugs and Other Directions, Shenzhen Fully Supports Pharmaceutical R&D and Introduction

Promoting High-Quality Development of Innovative Pharmaceuticals like Cell and Gene Therapy, Nine Departments Including the Beijing Municipal Medical Security Bureau Issue New Policies

A Cell Therapy Company in China Completes Pre-A Round Financing

SoundNote: The content is sourced from the company's official channels, thisWenPurposeInKnowRecognize CommonalityAll content is for reference only and does not constitute any advice.